Chewable tablet and method of formulating

• US 20080145423A1
• Filed: 12/14/2006
• Published: 06/19/2008
• Est. Priority Date: 12/14/2006
• Status: Abandoned Application

• Current Assignee: MSD CONSUMER PRODUCTS Incorporated (Merck & Co., Inc.)
• Original Assignee: MSD CONSUMER PRODUCTS Incorporated (Merck & Co., Inc.)
• Inventors: Brunson, Eddie, Khan, Ajmal Ali
• Application Number:
  US11/639,016
• Publication Number:
  US 20080145423A1
• Time in Patent Office: Days
• US Class Current: 424/465
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00

Abstract

Processes for preparing a chewable tablet comprising a micronized form of an active ingredient, the method comprising the steps of combining the active ingredient with tablet excipients by geometric dilution to form a final mixture and applying direct compression to at least a portion of the final mixture to form at least one tablet.

Claims

1. A process for preparing a chewable tablet comprising a micronized form or submicron form of an active ingredient, the method comprising the steps of combining the active ingredient with tablet excipients by geometric dilution to form a final mixture and applying direct compression to at least a portion of the final mixture to form at least one tablet.

2. The process according to claim 1, wherein the active ingredient is chosen from the group consisting of adrenergics;

adrenocortical steroids;

adrenocortical suppressants;

aldosterone antagonists;

amino acids;

anabolics;

analeptics;

analgesics;

anesthetics;

anorectics;

antiacne agents;

antiadrenergics;

antiallergics;

antiamebics;

antianemics;

antianginals;

antiarthritics;

antiasthmatics;

antiatherosclerotics;

antibacterials;

anticholinergics;

anticoagulants;

anticonvulsants;

antidepressants;

antidiabetics;

antidiarrheals;

antidiuretics;

antiemetics;

antiepileptics;

antifibrinolytics;

antifungals;

antihemorrhagics;

antihistamines;

antihyperlipidemics;

antihypertensives;

antihypotensives;

antiinfectives;

antiinflammatories;

antimicrobials;

antimigraine;

antimitotics;

antimycotics, antinauseants, antineoplastics, antineutropenics, antiparasitics;

antiproliferatives;

antipsychotics;

antirheumatics;

antiseborrheics;

antisecretories;

antispasmodics;

antithrombotics;

antiulceratives;

antivirals;

appetite suppressants;

blood glucose regulators;

bone resorption inhibitors;

bronchodilators;

cardiovascular agents;

cholinergics;

depressants;

diagnostic aids;

diuretics;

dopaminergic agents;

estrogen receptor agonists;

fibrinolytics;

fluorescent agents;

free oxygen radical scavengers;

gastrointestinal motility effectors;

glucocorticoids;

hair growth stimulants;

hemostatic agents;

histamine H₂ receptor antagonists;

hormones;

hypocholesterolemics;

hypoglycemics;

hypolipidemics;

hypotensives;

imaging agents;

immunizing agents;

immunomodulators;

immunoregulators;

immunostimulants;

immunosuppressants;

keratolytics;

LHRH agonists;

mood regulators;

mucolytics;

mydriatics;

nasal decongestants;

neuromuscular blocking agents;

neuroprotective agents;

NMDA antagonists;

non-hormonal sterol derivatives;

plasminogen activators;

platelet activating factor antagonists;

platelet aggregation inhibitors;

psychotropics;

radioactive agents;

scabicides;

sclerosing agents;

sedatives;

sedative-hypnotics;

selective adenosine AI antagonists;

serotonin antagonists;

serotonin inhibitors;

serotonin receptor antagonists;

steroids;

thyroid hormones;

thyroid inhibitors;

thyromimetics;

tranquilizers;

amyotrophic lateral sclerosis agent;

cerebral ischemia agent;

Paget'"'"'s disease agent;

unstable angina agent;

vasoconstrictor;

vasodilator;

wound healing agent;

xanthine oxidase inhibitor;

anti-cancer agents, and combinations thereof.

3. The process according to claim 2, wherein the active ingredient is an antihistamine.

4. The process according to claim 3, wherein the active ingredient is loratadine or desloratadine.

5. The process according to claim 1, wherein the active ingredient is present in an amount up to about 2.0 weight %.

35. A chewable tablet prepared by the process according to claims 1, 6, and 33.

6. A process for preparing a chewable tablet from a composition comprising an amount of at least one active ingredient in micronized form or submicron form and a plurality of tableting excipients, wherein the chewable tablet exhibits acceptable content uniformity of active ingredient, the process comprising:

a) dividing a first tableting excipient into a plurality of portions;

b) combining a percentage of the amount of the active ingredient with a first portion of the first tableting excipient in the absence of additional tableting excipients to form a primary premixture;

c) combining one or more additional tableting excipients from the plurality of tableting excipients into one or more remaining portions of the first tableting excipient not containing the active ingredient to form one or more secondary premixtures;

d) adding said one or more secondary premixtures to the primary premixture to form a main batch; and

e) applying direct compression to at least a portion of the main batch to form at least one tablet.

7. The process of claim 6, wherein the percentage of the amount of the active ingredient added to said first portion of said first tableting excipient is greater than 50%.

8. The process of claim 6, wherein the percentage of the amount of the active ingredient added to said first portion of said first tableting excipient is greater than 75%.

9. The process of claim 6, wherein the percentage of the amount of the active ingredient added to said first portion of said first tableting excipient is greater than 80%.

10. The process of claim 6, wherein the percentage of the amount of the active ingredient added to said first portion of said first tableting excipient is greater than 90%.

11. The process of claims 7-10, wherein the remainder of the amount of active ingredient is added to one or more of the secondary premixtures.

12. The process of claim 6, wherein the percentage of the amount of the active ingredient added to said first portion of said first tableting excipient is 100%.

13. The process of claim 6, wherein said first tableting excipient is the largest component of the composition by weight percentage of the total composition.

14. The process of claim 6, wherein said secondary premixtures are separately added to the primary premixture.

15. The process of claim 6, wherein at least two of said secondary premixtures are combined prior to being added to the primary premixture.

16. The process of claim 6, wherein the first tableting excipient is de-agglomerated by passing through a mill prior to step (a).

17. The process of claim 6, wherein the first tableting excipient is de-agglomerated by passing through a mill prior to step (b).

18. The process of claim 6, wherein one or more of said primary premixture and said one or more secondary premixtures are de-agglomerated by milling prior to step (d).

19. The process of claim 6, wherein one or more of said primary premixture and said one or more secondary premixtures are de-agglomerated by passing through a screen prior to step (d).

20. The process of claim 6, further comprising the step of combining one or more tableting excipients with at least a portion of said main batch to form a tertiary premixture and then adding said tertiary premixture to said main batch.

21. The process of claim 20, wherein said tertiary premixture is passed through a screen prior to its being added to said main batch.

22. The process of claim 6, wherein the tableting excipients are chosen from the group consisting of agents that impart desired attributes of chewablity and mouth feel, flow aids, disintegrants, lubricants, mold release agents, sweeteners and flavorants, colorants, stabilizers, adjuvants, corrosion inhibitors, dyes, surfactants, synergists, effervescents, diluents, builders, chelating agents, buffers, and mixtures thereof.

23. The process according to claim 6, wherein the first tableting excipient is a sweetener.

24. The process according to claim 23, wherein the sweetener is chosen from the group consisting of aspartame, dextrates, dextrose, fructose, mannitol, sodium saccharinate, calcium saccharinate, sorbitol, sucralose, sucrose, and mixtures thereof.

25. The process according to claim 6, wherein the first tableting excipient is mannitol.

26. The process according to claim 6, wherein the one or more active ingredients are chosen from the group consisting of adrenergics;

adrenocortical steroids;

adrenocortical suppressants;

aldosterone antagonists;

amino acids;

anabolics;

analeptics;

analgesics;

anesthetics;

anorectics;

antiacne agents;

antiadrenergics;

antiallergics;

antiamebics;

antianemics;

antianginals;

antiarthritics;

antiasthmatics;

antiatherosclerotics;

antibacterials;

anticholinergics;

anticoagulants;

anticonvulsants;

antidepressants;

antidiabetics;

antidiarrheals;

antidiuretics;

antiemetics;

antiepileptics;

antifibrinolytics;

antifungals;

antihemorrhagics;

antihistamines;

antihyperlipidemics;

antihypertensives;

antihypotensives;

antiinfectives;

antiinflammatories;

antimicrobials;

antimigraine;

antimitotics;

antimycotics, antinauseants, antineoplastics, antineutropenics, antiparasitics;

antiproliferatives;

antipsychotics;

antirheumatics;

antiseborrheics;

antisecretories;

antispasmodics;

antithrombotics;

antiulceratives;

antivirals;

appetite suppressants;

blood glucose regulators;

bone resorption inhibitors;

bronchodilators;

cardiovascular agents;

cholinergics;

depressants;

diagnostic aids;

diuretics;

dopaminergic agents;

estrogen receptor agonists;

fibrinolytics;

fluorescent agents;

free oxygen radical scavengers;

gastrointestinal motility effectors;

glucocorticoids;

hair growth stimulants;

hemostatic agents;

histamine H₂ receptor antagonists;

hormones;

hypocholesterolemics;

hypoglycemics;

hypolipidemics;

hypotensives;

imaging agents;

immunizing agents;

immunomodulators;

immunoregulators;

immunostimulants;

immunosuppressants;

keratolytics;

LHRH agonists;

mood regulators;

mucolytics;

mydriatics;

nasal decongestants;

neuromuscular blocking agents;

neuroprotective agents;

NMDA antagonists;

non-hormonal sterol derivatives;

plasminogen activators;

platelet activating factor antagonists;

platelet aggregation inhibitors;

psychotropics;

radioactive agents;

scabicides;

sclerosing agents;

sedatives;

sedative-hypnotics;

selective adenosine AI antagonists;

serotonin antagonists;

serotonin inhibitors;

serotonin receptor antagonists;

steroids;

thyroid hormones;

thyroid inhibitors;

thyromimetics;

tranquilizers;

amyotrophic lateral sclerosis agent;

cerebral ischemia agent;

Paget'"'"'s disease agent;

unstable angina agent;

vasoconstrictor;

vasodilator;

wound healing agent;

xanthine oxidase inhibitor;

anti-cancer agents, and combinations thereof.

27. The process according to claim 26, wherein the active ingredient is an antihistamine.

28. The process according claim 27, wherein two of said chewable tablets exhibits bioequivalence to one non-chewable tablet comprising an equal or similar amount of antihistamine.

29. The process according to claim 27, wherein the active ingredient is loratadine or desloratadine.

30. The process according to claim 6, wherein the active ingredient is present in an amount up to about 2.0 weight %.

31. The process according to claim 6, wherein the active ingredient is in micronized form.

32. The process according to claim 6, wherein the active ingredient is in submicron form.

33. A process for preparing a chewable tablet comprising an antihistamine in micronized form or submicron form and tableting excipients, the method comprising the steps of combining the loratadine with tableting excipients by geometric dilution to form a final mixture and applying direct compression on the final mixture to produce tablet shapes, wherein any two of said chewable tablets exhibits bioequivalence to one nonchewable tablet comprising an equal or similar amount of antihistamine.

34. The process according to claim 33, wherein the antihistamine is loratadine or desloratadine.

36. A chewable tablet comprising an antihistamine in micronized form or submicron form and tableting excipients, wherein the chewable tablet exhibits acceptable organoleptic qualities, antihistamine content uniformity, rapid dissolution, a substantial absence of binding in the die cavities and a substantial absence of sticking to punch faces under compression.

37. The chewable tablet according to claim 36, wherein the antihistamine is loratadine or desloratadine.

38. The chewable tablet according to claim 37, wherein the antihistamine is loratadine and the loratadine is present in an amount up to about 2.0 weight % per tablet.